Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Financial flexibility is valuable, but it’s not everything - at StockStory, we help you find the stocks that can not only survive but also outperform. Keeping that in mind, here are three companies with net cash positions to avoid and some better alternatives instead.
Corcept (CORT)
Net Cash Position: $328.5 million (3.7% of Market Cap)
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Are We Hesitant About CORT?
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 19.4% annually while its revenue grew
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 31 percentage points
- Waning returns on capital imply its previous profit engines are losing steam
At $92.05 per share, Corcept trades at 76x forward P/E. If you’re considering CORT for your portfolio, see our FREE research report to learn more.
Enterprise Financial Services (EFSC)
Net Cash Position: $213 million (9.2% of Market Cap)
Starting as a single bank in Missouri in 1988 and expanding through strategic growth, Enterprise Financial Services (NASDAQ: EFSC) is a financial holding company that offers banking, lending, and wealth management services to businesses and individuals across seven states.
Why Does EFSC Give Us Pause?
- Muted 7.7% annual revenue growth over the last two years shows its demand lagged behind its banking peers
- Costs have risen faster than its revenue over the last four years, causing its efficiency ratio to worsen by 8.7 percentage points
- Incremental sales over the last two years were less profitable as its 5.2% annual earnings per share growth lagged its revenue gains
Enterprise Financial Services’s stock price of $65.68 implies a valuation ratio of 1.2x forward P/B. Dive into our free research report to see why there are better opportunities than EFSC.
Dolby Laboratories (DLB)
Net Cash Position: $624.6 million (12.5% of Market Cap)
Known for its iconic "D" logo that appears before countless movies and TV shows, Dolby Laboratories (NYSE: DLB) designs and licenses audio and video technologies that enhance entertainment experiences in movies, TV shows, music, and other media.
Why Should You Dump DLB?
- Muted 2.1% annual revenue growth over the last five years shows its demand lagged behind its software peers
- Extended payback periods on sales investments suggest the company’s platform isn’t resonating enough to drive efficient sales conversions
- Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 2 percentage points
Dolby Laboratories is trading at $50.54 per share, or 3.4x forward price-to-sales. Check out our free in-depth research report to learn more about why DLB doesn’t pass our bar.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
